片仔癀温肺定喘颗粒Ⅱ期临床试验完成首例受试者入组

Core Viewpoint - The company Pianzaihuang (片仔癀) has announced the completion of the first subject enrollment for its Phase II clinical trial of "Wenfei Dingchuan Granules" aimed at treating stable chronic obstructive pulmonary disease (COPD) [1] Group 1: Clinical Trial Details - The clinical trial is randomized, double-blind, placebo-controlled, dose-exploration, and multi-center [1] - The trial focuses on the treatment of COPD characterized by lung and kidney qi deficiency with phlegm and blood stasis [1] Group 2: Product Information - Wenfei Dingchuan Granules are derived from clinical experience and are intended to supplement lung and warm kidney, stop cough and relieve asthma, and resolve phlegm and eliminate stasis [1] - The product is aimed at symptoms such as cough, sputum, wheezing, fatigue, lower back and knee soreness, aversion to wind, cold intolerance, and specific tongue and pulse characteristics [1]